Cancer Therapeutics Crc Pty Limited

Ian Peter Holmes

Richard Charles Foitzik

Romina Lessene

Danny Ganame

Gillian Elizabeth Lunniss

Catherine Fae Hemley

Scott Raymond Walker

Neil Choi

Paul Anthony Stupple

Michelle Ang Camerino

Ylva Elisabet Bergman

Wilhelmus Johannes Antonius Kersten

Marica Nikac

Andrew John Harvey

Benjamin Joseph Morrow

Yiva Bergman

Ylva Bergman

Alexandra Elizabeth Stupple

Helen Rachel Lagiakos

Marcia Nikac

Neil Chol

Gillian Elizabeth Lunnis

Jo-Anne Pinson

Substituted benzimidazole and 3H-imidazo[4,5-b]pyridines or formula I: where X and Y respectively are selected from: (i) N and N; and (ii) N and CR; Ais selected from: a Cheteroarylene group, containing 2 or 3 ring heteroatoms, where the bonds to L1 and the core are &#x3b2; to one another; Lis selected from: (i)&#x2014;O&#x2014;CH&#x2014;; (ii)&#x2014;CH&#x2014;O&#x2014;; (iii)&#x2014;C(&#x2550;O)&#x2014;NH&#x2014;; (iv)&#x2014;CH(OH)&#x2014;; (v)&#x2014;CH&#x2014;NH&#x2014;C(&#x2550;O)&#x2014;; (vi)&#x2014;S&#x2014;CH&#x2014;; (vii)&#x2014;CH&#x2014;S&#x2014;; (viii)&#x2014;CH&#x2014;; and (ix)&#x2014;CH(CH)&#x2014;O&#x2014;; A1 is phenyl, optionally substituted by F or CF; their use as pharmaceuticals, and in particular, in treating cancer and hemoglobinopathies. 

2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferase

A compound of the formula (I): where Ror Ris a cyclic amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

FAK inhibitors

This invention relates to compounds of the formula (I): The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

VEGFR3 inhibitors

This invention relates to a compound of the formula (I):  The invention also relates to processes for the preparation of the compound of the formula (I), pharmaceutical agents or compositions containing the compound or a method of using the compound for the treatment of proliferative diseases, such as cancer, as well as the treatment of diseases ameliorated by the control and/or inhibition of lymphangiogenesis.

A compound of the formula (I): where Ror Ris a cycle, amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Selective FAK inhibitors

A compound of the formula (I): where Ror Ris a cyclc amine group and Ris an aromatic group with a carbonyl containing substituent for use as a FAK inhibitor.

Growing community of inventors

Bundoora, Australia

Ian Peter Holmes